Precisio Biotix Therapeutics, Inc.
Precisio Biotix Therapeutics is a US-incorporated industry leader in precision antibacterial biological solutions, focusing on the development of lysin, phage, and amurin products and related delivery technologies to combat bacterial infections and address unmet medical needs. The company aims to provide low-cost antibacterials globally through its platform-plus-product drug discovery and development approach, with a focus on both Rx and consumer products. Its mission is to become a world leader in anti-bacterial solutions, saving lives and improving antibacterial treatments.
Industries
Nr. of Employees
medium (51-250)
Precisio Biotix Therapeutics, Inc.
Patents
Disinfection of bacteriophages products using supercritical carbon dioxide
US-12232492-B2
View DetailsComposition comprising amino acid polymers and a bioactive agent and method of preparing thereof
US-11564894-B2
View DetailsComposition comprising a polymer and a bioactive agent and method of preparing thereof
US-10772964-B2
View Details
Disinfection of bacteriophages products using supercritical carbon dioxide
US-12232492-B2
View DetailsComposition comprising amino acid polymers and a bioactive agent and method of preparing thereof
US-11564894-B2
View DetailsComposition comprising a polymer and a bioactive agent and method of preparing thereof
US-10772964-B2
View DetailsProducts
Sustained-release topical phage therapy for prevention/treatment of pressure-ulcer and chronic wound infections
Topical sustained-release formulation that encapsulates bacteriophages to penetrate wound beds and provide prolonged phage release for prevention and treatment of antimicrobial-resistant topical infections; development pathway includes Phase I/II clinical trials.
Topical lysin therapies for eczema
Topical recombinant lysin formulation targeting Staphylococcus aureus colonization associated with atopic dermatitis/eczema to reduce pathogenic burden.
Topical lysin therapy for acne (Cutibacterium acnes targeting)
First-in-class lysin-based topical product designed to target Cutibacterium acnes (and adjunct staphylococcal contributors) to treat acne vulgaris.
Biodegradable sustained-release topical polymer for biologics
A biodegradable amino-acid based copolymer delivery material for microencapsulation and controlled release of biologics and chemical agents in topical applications.
Sustained-release topical phage therapy for prevention/treatment of pressure-ulcer and chronic wound infections
Topical sustained-release formulation that encapsulates bacteriophages to penetrate wound beds and provide prolonged phage release for prevention and treatment of antimicrobial-resistant topical infections; development pathway includes Phase I/II clinical trials.
Topical lysin therapies for eczema
Topical recombinant lysin formulation targeting Staphylococcus aureus colonization associated with atopic dermatitis/eczema to reduce pathogenic burden.
Topical lysin therapy for acne (Cutibacterium acnes targeting)
First-in-class lysin-based topical product designed to target Cutibacterium acnes (and adjunct staphylococcal contributors) to treat acne vulgaris.
Biodegradable sustained-release topical polymer for biologics
A biodegradable amino-acid based copolymer delivery material for microencapsulation and controlled release of biologics and chemical agents in topical applications.
Services
Pilot-scale fermentation, protein production, downstream purification and fill-finish services in BSL2/GMP-capable facilities.
Large-scale sequence analysis and AI-driven prioritization to generate and optimize lysin candidates for targeted bacterial species.
Design and execution of biochemical, microbiological and in vivo assays for antibacterial candidate validation and IND-enabling studies.
Structuring out-licensing agreements, regional partnerships and commercialization pathways including regulatory filing support in targeted jurisdictions.
Pilot-scale fermentation, protein production, downstream purification and fill-finish services in BSL2/GMP-capable facilities.
Large-scale sequence analysis and AI-driven prioritization to generate and optimize lysin candidates for targeted bacterial species.
Design and execution of biochemical, microbiological and in vivo assays for antibacterial candidate validation and IND-enabling studies.
Structuring out-licensing agreements, regional partnerships and commercialization pathways including regulatory filing support in targeted jurisdictions.
Expertise Areas
- Lysin discovery and engineering
- Phage therapeutics and topical delivery
- Sustained-release biodegradable topical delivery
- Biologics manufacturing and scale-up
Key Technologies
- High-throughput screening
- Endolysin bioinformatics design
- AI-driven candidate selection
- Biologic engineering for Gram-negative activity
News & Updates
The announcement by Mark Engel, Precisio Biotix's Chairman and CEO, highlights another step by Precisio Biotix to advance novel precision biological antibacterials.
The announcement by Mark Engel, Precisio Biotix's Chairman and CEO, signifies a greater commitment to globalizing the Company's antibacterial science.
The announcement by Mark Engel, the Company's Chairman and CEO, signifies a greater commitment to the US market.
The management team of Precisio Biotix Therapeutics, a company that develops novel precision biological antibacterial products, is proud to announce that effective July 2, 2023, it is a management owned and controlled company.
Phagelux, Inc. is proud to announce the change of name of its Wuhan-based subsidiary to Lysigen.
Phagelux, Inc. is proud to announce the out-licensing of its staphylococcus lysin to Shanghai Pharmaceutical Holdings Co. for in vivo applications.
The announcement by Mark Engel, Precisio Biotix's Chairman and CEO, highlights another step by Precisio Biotix to advance novel precision biological antibacterials.
The announcement by Mark Engel, Precisio Biotix's Chairman and CEO, signifies a greater commitment to globalizing the Company's antibacterial science.
The announcement by Mark Engel, the Company's Chairman and CEO, signifies a greater commitment to the US market.
The management team of Precisio Biotix Therapeutics, a company that develops novel precision biological antibacterial products, is proud to announce that effective July 2, 2023, it is a management owned and controlled company.
Phagelux, Inc. is proud to announce the change of name of its Wuhan-based subsidiary to Lysigen.
Phagelux, Inc. is proud to announce the out-licensing of its staphylococcus lysin to Shanghai Pharmaceutical Holdings Co. for in vivo applications.